secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K/A
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001193125-23-278012
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical files pro forma financials for NuVasive Merger; combined net income $6M for 9 months
--------------------------------------------------------------------------------

- Pro forma net income for nine months ended Sep 30, 2023: $6.0M ($0.04 diluted EPS) vs Globus standalone $107.8M.
- Total purchase price $2.6B; goodwill $924M, intangible assets $1.22B (developed tech, customer relationships).
- Pro forma net income for FY2022: $5.2M ($0.04 diluted EPS) vs Globus standalone $190.2M.
- NuVasive contributed $827M revenue for Jan–Aug 2023; inventory step-up of $284M added to cost of sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000119312523278012/0001193125-23-278012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000119312523278012/d315801d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-278012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer